Effect of gabexate mesylate (FOY), a drug for serine proteinase-mediated diseases, on the nitric oxide pathway

Marco Colasanti, Tiziana Persichini, Giorgio Venturini, Enea Menegatti, Giuliana M. Lauro, Paolo Ascenzi

Research output: Contribution to journalArticle

Abstract

Considering the structural similarity between gabexate mesylate (FOY), a drug for serine proteinase-mediated diseases, and L-arginine, the effect of gabexate mesylate on the nitric oxide (NO) pathway has been investigated. Gabexate mesylate inhibits competitively constitutive and inducible NO synthase (cNOS and iNOS, respectively), with K(i) values of 1.0 x 10-4 M and 5.0 x 10-3 M, respectively, at pH 7.4 and 37.O°C. However, gabexate mesylate is not an NO precursor. Moreover, like other NOS inhibitors, gabexate mesylate increases iNOS mRNA expression in rat C6 glioma cells, as induced by E. coli lipopolysaccharide plus interferon-γ. Finally, gabexate mesylate inhibits dose-dependently nitrite production (i.e. NO release) in rat C6 glioma cells, as induced by E. coli lipopolysaccharide plus interferon-γ. Thus, this drug should be administered under careful control, since enzyme inhibition may occur also in vivo.

Original languageEnglish
Pages (from-to)453-456
Number of pages4
JournalBiochemical and Biophysical Research Communications
Volume246
Issue number2
DOIs
Publication statusPublished - May 19 1998

    Fingerprint

Keywords

  • FOY
  • Gabexate mesylate
  • NO
  • NO synthase
  • Rat C6 glioma cells

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this